tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Robyn Karnauskas, 384 are a BUY (86.49%), 58 are a HOLD (13.06%), 2 are a SELL (0.45%).
Analyst Robyn Karnauskas, carries an average stock price target met ratio of 57.21% that have a potential upside of 37.76% achieved within 418 days. Previously, Robyn Karnauskas worked at TRUIST, DEUTSCHE BANK, CITI.
Robyn Karnauskas’s has documented 878 price targets and ratings displayed on 51 stocks. The coverage was on Healthcare, Technology, Energy sectors.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 19-Nov-2025.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for FATE (FATE THERAPEUTICS) at 1/5/2023. The price target of $7 was fulfilled within 1 day with a profit of $4 (36.36%) receiving and performance score of 363.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 18-Nov-2020
$273
$19.65 (7.76%)
$262
15 days ago
(23-Jun-2026)
14/16 (87.5%)
$38.24 (16.29%)
409
Buy Since 12-Sep-2025
$298
$44.65 (17.62%)
$298
15 days ago
(23-Jun-2026)
2/7 (28.57%)
$63.24 (26.94%)
35
Buy Since 23-Jan-2023
$235
$-18.35 (-7.24%)
$236
1 months 23 days ago
(15-May-2026)
8/8 (100%)
$24.61 (11.70%)
142
Buy Since 06-Feb-2020
$249
$-4.35 (-1.72%)
$249
2 months 7 days ago
(01-May-2026)
35/35 (100%)
$42.4 (20.52%)
446
Buy Since 24-Jan-2022
$278
$24.65 (9.73%)
$270
2 months 8 days ago
(30-Apr-2026)
21/24 (87.5%)
$66.68 (31.55%)
515
What Year was the first public recommendation made by Robyn Karnauskas?
